{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:10:39Z","timestamp":1759666239195},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die membran\u00f6se Nephropathie (MN) ist eine Immunkomplex-Glomerulonephritis und z\u00e4hlt zu den h\u00e4ufigsten Ursachen f\u00fcr ein nephrotisches Syndrom beim Erwachsenen und z\u00e4hlt zu den autoimmunen Nierenerkrankungen mit der h\u00f6chsten Rate an Spontanremissionen. Das h\u00e4ufigste Autoantigen (&gt;\u202f70\u202f% der F\u00e4lle) ist gegen den Phospholipase-A2-Rezeptor (PLA2-R) gerichtet und erlaubt mit seinem Nachweis und Verlauf eine hervorragende Diagnostik sowie auch ein optimales Therapiemonitoring. Andere Autoantigene werden laufend ver\u00f6ffentlicht und werden k\u00fcnftig einen autoantigen-basierten Diagnose- und Therapiealgorithmus der MN erm\u00f6glichen. Bei fehlender Spontanremission stellt eine spezifische B\u2011Zell-gerichtete Therapie, insbesondere mit Rituximab die initiale Therapie der Wahl dar. Kalzineurin-Inhibitoren oder Cyclophosphamid sollen erst bei sorgsamer Indikation im jeweiligen klinischen Kontext wie bei ernsthaften klinischen Konsequenzen sowohl durch das nephrotische Syndrom als auch bei Nierenfunktionsverlust erwogen werden. Da renale Immunkomplexe oft lange Zeit ben\u00f6tigen, um abgebaut zu werden, kann eine gro\u00dfe Proteinurie der immunologischen Remission durchaus \u00fcber viele Monate hinterherlaufen, bis es schlie\u00dflich zu einer Abnahme oder Resolution der Proteinurie kommt. Die Therapie der MN stellt den g\u00fcnstigen Fall einer pr\u00e4zisionsmedizinisch-basierten Therapie in der Nephrologie dar, wobei neue therapeutische B\u2011Zellantik\u00f6rper f\u00fcr die seltenen, aber schwierigen Verlaufsformen der MN in naher Zukunft Eingang in die klinische Routine finden werden.<\/jats:p>","DOI":"10.1007\/s00508-023-02261-w","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:01:56Z","timestamp":1695214916000},"page":"648-655","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostik und Therapie der Membran\u00f6sen Nephropathie\u00a0\u2013 2023","Diagnosis and therapy of membranous nephropathy\u20142023"],"prefix":"10.1007","volume":"135","author":[{"given":"Marcus D.","family":"S\u00e4emann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Odler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Regele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irmgard","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Gauckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Knechtelsdorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"2261_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco\u00a0P, Beck\u00a0L, Debiec\u00a0H, Fervenza\u00a0FC, Hou\u00a0FF, Jha\u00a0V, et\u00a0al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7:69.","journal-title":"Nat Rev Dis Primers"},{"key":"2261_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","volume":"18","author":"E Hoxha","year":"2022","unstructured":"Hoxha\u00a0E, Reinhard\u00a0L, Stahl\u00a0RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18:466\u201378.","journal-title":"Nat Rev Nephrol"},{"key":"2261_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/ndt\/gfab356","volume":"38","author":"P Ronco","year":"2023","unstructured":"Ronco\u00a0P, Plaisier\u00a0E, Debiec\u00a0H. The role of PLA2R antibody monitoring: what we know and what we don\u2019t know. Nephrol Dial Transplant. 2023;38:826\u201333.","journal-title":"Nephrol Dial Transplant"},{"key":"2261_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","volume":"68","author":"JM Francis","year":"2016","unstructured":"Francis\u00a0JM, Beck\u00a0LH, Salant\u00a0DJ. Membranous nephropathy: a\u00a0journey from bench to bedside. Am J Kidney Dis. 2016;68:138\u201347.","journal-title":"Am J Kidney Dis"},{"key":"2261_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1309\/AJCP8QMOY5GLRSFP","volume":"142","author":"SAMEG Timmermans","year":"2014","unstructured":"Timmermans\u00a0SAMEG, Damoiseaux\u00a0JGMC, Heerings-Rewinkel\u00a0PTJ, Ayalon\u00a0R, Beck\u00a0LH, Schlumberger\u00a0W, et al. Evaluation of anti-PLA2R1 as measured by a\u00a0novel ELISA in patients with idiopathic membranous nephropathy: a\u00a0cohort study. Am J Clin Pathol. 2014;142:29\u201334.","journal-title":"Am J Clin Pathol"},{"key":"2261_CR6","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2215\/CJN.05480421","volume":"16","author":"SA Bobart","year":"2021","unstructured":"Bobart\u00a0SA, Han\u00a0H, Tehranian\u00a0S, De Vriese\u00a0AS, Roman\u00a0JCL, Sethi\u00a0S, et al. Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a\u00a0validation study. Clin J Am Soc Nephrol. 2021;16:1833\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2261_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese\u00a0AS, Glassock\u00a0RJ, Nath\u00a0KA, Sethi\u00a0S, Fervenza\u00a0FC. A\u00a0proposal for a\u00a0serology-based approach to membranous nephropathy. J\u00a0Am Soc Nephrol. 2017;28:421\u201330.","journal-title":"J Am Soc Nephrol"},{"key":"2261_CR8","unstructured":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases\u2014kidney international. Kidney Int. 2021 Oct;100(4S):S1-S276. https:\/\/www.kidney-international.org\/article\/S0085-2538(21)00562\u20117."},{"key":"2261_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ndt\/gfab316","volume":"37","author":"F Caravaca-Font\u00e1n","year":"2022","unstructured":"Caravaca-Font\u00e1n\u00a0F, Fern\u00e1ndez-Ju\u00e1rez\u00a0GM, Floege\u00a0J, Goumenos\u00a0D, Kronbichler\u00a0A, Turkmen\u00a0K, et al. The management of membranous nephropathy\u2014an update. Nephrol Dial Transplant. 2022;37:1033\u201342.","journal-title":"Nephrol Dial Transplant"},{"key":"2261_CR10","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.34067\/KID.0002492021","volume":"2","author":"N Klomjit","year":"2021","unstructured":"Klomjit\u00a0N, Zand\u00a0L. Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: COMMENTARY. Kidney360. 2021;2:1702\u20135.","journal-title":"Kidney360"},{"key":"2261_CR11","doi-asserted-by":"publisher","first-page":"789713","DOI":"10.3389\/fimmu.2022.789713","volume":"13","author":"F Scolari","year":"2022","unstructured":"Scolari\u00a0F, Alberici\u00a0F, Mescia\u00a0F, Delbarba\u00a0E, Trujillo\u00a0H, Praga\u00a0M, et\u00a0al. Therapies for membranous nephropathy: a\u00a0tale from the old and new millennia. Front Immunol. 2022;13:789713.","journal-title":"Front Immunol"},{"key":"2261_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000368589","volume":"128","author":"P Cravedi","year":"2014","unstructured":"Cravedi\u00a0P, Remuzzi\u00a0G, Ruggenenti\u00a0P. Rituximab in primary membranous nephropathy: first-line therapy, why not? Nephron Clin Pract. 2014;128:261\u20139.","journal-title":"Nephron Clin Pract"},{"key":"2261_CR13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.34067\/KID.0001842021","volume":"2","author":"N Oliva-Damaso","year":"2021","unstructured":"Oliva-Damaso\u00a0N, Bomback\u00a0AS. Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: PRO. Kidney360. 2021;2:1696\u20138.","journal-title":"Kidney360"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02261-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02261-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:17:53Z","timestamp":1695215873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02261-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":13,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02261-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.\u00a0S\u00e4emann, B.\u00a0Odler, M.\u00a0Windpessl, H.\u00a0Regele, K.\u00a0Eller, I.\u00a0Neumann, M.\u00a0Rudnicki, P.\u00a0Gauckler, A.\u00a0Kronbichler und M.\u00a0Knechtelsdorfer geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}